Navigation Links
Trubion Announces Presentations at April/May Investor Conferences
Date:4/24/2008

SEATTLE, April 24 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that executives will present an overview of the company at two upcoming investor conferences in April and May:
-- April 30: Morgan Stanley Global Healthcare Unplugged Conference at The

Ritz-Carlton, 455 Grand Bay Drive in Key Biscayne, FL. Dr. Peter

Thompson, president, CEO and chairman, is scheduled to present at

9:50 a.m. EDT. The presentation will be available via audio Webcast at

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TRBN&item_id=18.

-- May 13: Bank of America 2008 Health Care Conference at the Four

Seasons, 3960 Las Vegas Blvd S in Las Vegas, NV. Michelle Burris,

senior vice president and chief financial officer, is scheduled to

present at 1:20 p.m. PDT. The presentation will be available via audio

Webcast at

http://www.veracast.com/webcasts/bas/healthcare08/id62101185.cfm.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases developed under the company's Wyeth collaboration. Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

For more information, contact:

Trubion Pharmaceuticals, Inc.

Jim DeNike

Senior Director, Corporate Communications

206-838-0500

jdenike@trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

617-576-5788

amyp@waggeneredstrom.com TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
2. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
5. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
6. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
7. Abbott Announces Labs Are Vital(TM) Facebook Scholarship Contest Winners
8. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers
9. Inverness Medical Innovations Announces First Quarter 2008 Results
10. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
11. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... today announced the appointment of Joshua F. Coleman , ... Dr. Coleman will oversee clinical content development and curation of ... software suite empowers molecular pathologists with a seamless workflow for ... from quality control through reporting. ... , , ...
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
(Date:11/30/2016)... 30. November 2016   Merck , ... die Unterzeichnung einer Reihe von Vereinbarungen mit ... Evotec AG Screeningleistungen für Mercks Palette genetischer ... Zugriff auf diese Bibliotheken in Kombination mit ... schnelleren Weg zur Ermittlung und Erforschung neuer ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... technology applications, introduces the 5th generation, ultra-bright, Laser-Driven Light Source, the EQ-77, at ... Source (LDLS™) technology, the EQ-77 offers higher radiance and irradiance from a truly ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):